It also said it reported total operating income of RON399.9 million in January-June 2020, down 18.1% on the year, per ZF calculations based on the company’s half-year financial report.
The company had operating expenses of RON398.5 million in the first six months of 2020, down 3.14% on the year, which triggered an operating profit of RON1.5 million, twice lower the result posted in the year-earlier period, per ZF calculations.
Its earnings before interest, taxes, depreciation, and amortization (EBITDA) fell 14% on the year to RON11.9 million in January-June 2020.
Of the companies part of the Group, Ropharma SA reported sales of RON231.5 million in the first half of 2020, obtained from the sale of prescription drugs (RON166.5 million) and from the sale of over-the-counter (OTC) drugs (RON65 million).
On the pharmaceutical retail market, Ropharma SA had a market of share of 3.5% in the first half of 2020, ranking fifth along local pharmacy chains.
On June 30, 2020, Ropharma’s shareholding structure included Arrow Pharmaceuticals (31.2%), ADD Pharmaceuticals Limited (17.6%), Rimia Investments Limited (14%), offshores held by Mihai Miron, the company’s Executive Board Chairman and Chief Executive Officer, private pension fund Fondul de Pensii Privat Allianz (8.9%) and GOA Capital (3.9%), a company almost entirely held by broker Daniel Tepes, a former shareholder in the Bucharest Stock Exchange and Sibex.